BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 17053165)

  • 1. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
    Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
    J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
    J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
    Pillai A; Teo P; George T; Mukhopadhyay A; Dejbakhsh-Jones S; Strober S
    Bone Marrow Transplant; 2007 Sep; 40(5):487-97. PubMed ID: 17603512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity.
    Yamamoto S; Tsuji T; Matsuzaki J; Zhange Y; Chamoto K; Kosaka A; Togashi Y; Sekikawa K; Sawada K; Takeshima T; Koike T; Nishimura T
    Int Immunol; 2004 Jun; 16(6):811-7. PubMed ID: 15126416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction.
    Murai M; Yoneyama H; Ezaki T; Suematsu M; Terashima Y; Harada A; Hamada H; Asakura H; Ishikawa H; Matsushima K
    Nat Immunol; 2003 Feb; 4(2):154-60. PubMed ID: 12524535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
    Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
    Schattenfroh NC; Hoffman RA; McCarthy SA; Simmons RL
    Transplantation; 1995 Jan; 59(2):268-73. PubMed ID: 7839451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
    Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
    Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
    Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
    Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
    Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
    Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
    Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
    Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The flavonoid Kaempferol suppresses the graft-versus-host reaction by inhibiting type 1 cytokine production and CD8+ T cell engraftment.
    Okamoto I; Iwaki K; Koya-Miyata S; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
    Clin Immunol; 2002 May; 103(2):132-44. PubMed ID: 12027418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term homing assay reveals a critical role for lymphocyte function-associated antigen-1 in the hepatic recruitment of lymphocytes in graft-versus-host disease.
    Sato T; Habtezion A; Beilhack A; Schulz S; Butcher E; Thorlacius H
    J Hepatol; 2006 Jun; 44(6):1132-40. PubMed ID: 16466827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
    Har-Noy M; Slavin S
    Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
    Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
    Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.